Search clinical trials for: SAR245408 (XL147)

Total 33 results

Sanofi

Completed

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

Glioblastoma | Astrocytoma, Grade IV

United States
Sanofi

Completed

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

Endometrial Neoplasms | Endometrial Cancer

United States, Belgium
Sanofi

Completed

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

Lymphoma | Cancer

United States, Spain
Sanofi

Completed

Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
Sanofi

Completed

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Neoplasm Malignant

Spain, Belgium, United States, France
Sanofi

Completed

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Breast Cancer

United States, France, Spain
Exelixis

Withdrawn

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Cancer | Breast Cancer | Non-small-cell Lung Cancer

United States
Sanofi

Completed

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

Cancer | Non-small Cell Lung Cancer

United States
Sanofi

Completed

Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Cancer | Non-Small Cell Lung Cancer | Endometrial Carcinoma | Ovarian Carcinoma

United States
Sanofi

Completed

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

Neoplasm Malignant

Japan
Sanofi

Completed

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

Breast Cancer | Breast Neoplasms

United States, Spain
Sanofi

Completed

A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma

Neoplasm Malignant

Belgium
Sanofi

Completed

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Lymphoma

Germany, France, Belgium, Netherlands, United States, Australia
Sanofi

Completed

A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma

Neoplasm Malignant

United States
Sanofi

Completed

Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors

Cancer

United States, Spain
Sanofi
Merrimack Pharmaceuticals

Completed

A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers

Solid Tumor Cancers

United States
Kadmon Corporation, LLC

Completed

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Glioblastoma | Brain Tumor | Recurrent Glioblastoma

United States
Sanofi

Completed

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Indolent Non-Hodgkin Lymphoma

United States
EMD Serono
Sanofi

Completed

Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

Ovarian Cancer

United States, Belgium, Canada, Australia, Spain, France, Poland
Kadmon, a Sanofi Company

Completed

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

United States
Kadmon Corporation, LLC

Completed

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Non-Small Cell Lung Cancer | Brain Metastases | Leptomeningeal Metastases

United States
Sanofi

Completed

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Glioblastoma Multiforme | Malignant Gliomas | Mixed Gliomas

United States
Kadmon Corporation, LLC

Completed

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Carcinoma, Non-Small-Cell Lung

United States
Kadmon Corporation, LLC

Completed

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Non-small-cell Lung Cancer

United States
Sanofi

Completed

Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

Cancer | Non-Small Cell Lung Cancer

United States
Kadmon Corporation, LLC

Completed

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Cancer

United States
Kadmon Corporation, LLC

Completed

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Polycystic Kidney, Autosomal Recessive

United States
Kadmon Corporation, LLC

Completed

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Cancer

United States
Kadmon Corporation, LLC

Terminated

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Kadmon Corporation, LLC

Terminated

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States
Kadmon, a Sanofi Company

Completed

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney | ADPKD

United States
Kadmon Corporation, LLC

Terminated

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

HER-2 Positive Breast Cancer | Metastatic Malignant Neoplasm to Brain

United States
EMD Serono
Sanofi

Completed

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Melanoma | Breast Cancer | Colorectal Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States, Italy, Spain

3

Subscribe